Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioAtla, Inc.BCAB · Entity 879 | Chief Medical Officer | August 31, 2026 | September 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioAtla, Inc.
Report date August 31, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,346 |
Reported balance
After 2026-08-31 transaction · row 1
1 source rowRow 1 · 2026-08-31 · Tax withholding · Disposed 134 · Balance 11,346 F1: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 01, 2021 Filed Dec 7, 2021 22:41 UTC | BioAtla, Inc. BCAB · Entity 879 | SaleCommon Stock | 56 | $22.19 | $1,242.42 |
DisclosureSEC source: 0001209191-21-068384 · doc4.xml · nonDerivative · entry 4 Sievers Eric · CIK 0001835116 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,443 F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs. F5 · price: The range of prices for the shares of Common Stock is from $21.79 to $22.73. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. Read SEC document |
| November 30, 2021 Filed Dec 7, 2021 22:41 UTC | BioAtla, Inc. BCAB · Entity 879 | SaleCommon Stock | 20 | $25.38 | $507.58 |
DisclosureSEC source: 0001209191-21-068384 · doc4.xml · nonDerivative · entry 3 Sievers Eric · CIK 0001835116 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,499 F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs. F4 · price: The range of prices for the shares of Common Stock is from $25.30 to $25.38. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. Read SEC document |
| November 30, 2021 Filed Dec 7, 2021 22:41 UTC | BioAtla, Inc. BCAB · Entity 879 | SaleCommon Stock | 58 | $24.68 | $1,431.21 |
DisclosureSEC source: 0001209191-21-068384 · doc4.xml · nonDerivative · entry 2 Sievers Eric · CIK 0001835116 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,519 F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs. F3 · price: The range of prices for the shares of Common Stock is from $24.33 to $25.25. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. Read SEC document |
| November 30, 2021 Filed Dec 7, 2021 22:41 UTC | BioAtla, Inc. BCAB · Entity 879 | SaleCommon Stock | 53 | $24.00 | $1,271.84 |
DisclosureSEC source: 0001209191-21-068384 · doc4.xml · nonDerivative · entry 1 Sievers Eric · CIK 0001835116 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,577 F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs. F2 · price: The range of prices for the shares of Common Stock is from $23.33 to $24.32. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. Read SEC document |
| November 29, 2021 Filed Dec 7, 2021 01:41 UTC | BioAtla, Inc. BCAB · Entity 879 | SaleCommon Stock | 110 | $23.89 | $2,627.90 |
DisclosureSEC source: 0001209191-21-068212 · doc4.xml · nonDerivative · entry 1 Sievers Eric · CIK 0001835116 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,630 F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs. F2 · price: The range of prices for the shares of Common Stock is from $23.75 to $24.11. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. Read SEC document |
| November 24, 2021 Filed Dec 1, 2021 01:05 UTC | BioAtla, Inc. BCAB · Entity 879 | SaleCommon Stock | 37 | $25.77 | $953.53 |
DisclosureSEC source: 0001209191-21-067218 · doc4.xml · nonDerivative · entry 6 Sievers Eric · CIK 0001835116 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,740 F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs. F7 · price: The range of prices for the shares of Common Stock is from $25.57 to $26.14. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. Read SEC document |
| November 24, 2021 Filed Dec 1, 2021 01:05 UTC | BioAtla, Inc. BCAB · Entity 879 | SaleCommon Stock | 44 | $25.00 | $1,099.96 |
DisclosureSEC source: 0001209191-21-067218 · doc4.xml · nonDerivative · entry 5 Sievers Eric · CIK 0001835116 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,777 F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs. F6 · price: The range of prices for the shares of Common Stock is from $24.48 to $25.42. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. Read SEC document |
| November 24, 2021 Filed Dec 1, 2021 01:05 UTC | BioAtla, Inc. BCAB · Entity 879 | SaleCommon Stock | 48 | $24.05 | $1,154.54 |
DisclosureSEC source: 0001209191-21-067218 · doc4.xml · nonDerivative · entry 4 Sievers Eric · CIK 0001835116 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,821 F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs. F5 · price: The range of prices for the shares of Common Stock is from $23.48 to $24.32. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. Read SEC document |
| November 23, 2021 Filed Dec 1, 2021 01:05 UTC | BioAtla, Inc. BCAB · Entity 879 | SaleCommon Stock | 68 | $26.04 | $1,770.38 |
DisclosureSEC source: 0001209191-21-067218 · doc4.xml · nonDerivative · entry 3 Sievers Eric · CIK 0001835116 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,869 F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs. F4 · price: The range of prices for the shares of Common Stock is from $24.85 to $25.70. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. Read SEC document |
| November 23, 2021 Filed Dec 1, 2021 01:05 UTC | BioAtla, Inc. BCAB · Entity 879 | SaleCommon Stock | 119 | $24.29 | $2,889.92 |
DisclosureSEC source: 0001209191-21-067218 · doc4.xml · nonDerivative · entry 2 Sievers Eric · CIK 0001835116 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,937 F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs. F3 · price: The range of prices for the shares of Common Stock is from $23.82 to $24.79. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. Read SEC document |
| November 22, 2021 Filed Dec 1, 2021 01:05 UTC | BioAtla, Inc. BCAB · Entity 879 | SaleCommon Stock | 118 | $26.24 | $3,095.73 |
DisclosureSEC source: 0001209191-21-067218 · doc4.xml · nonDerivative · entry 1 Sievers Eric · CIK 0001835116 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,056 F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs. F2 · price: The range of prices for the shares of Common Stock is from $25.83 to $26.75. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. Read SEC document |
| October 01, 2021 Filed Oct 7, 2021 22:08 UTC | BioAtla, Inc. BCAB · Entity 879 | SaleCommon Stock | 592 | $30.39 | $17,993.43 |
DisclosureSEC source: 0001209191-21-059975 · doc4.xml · nonDerivative · entry 1 Sievers Eric · CIK 0001835116 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,174 F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs. F2 · price: The range of prices for the shares of Common Stock is from $30.20 to $30.47. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. Read SEC document |
| August 26, 2021 Filed Aug 31, 2021 01:42 UTC | BioAtla, Inc. BCAB · Entity 879 | SaleCommon Stock | 6,883 | $39.59 | $272,495.91 |
DisclosureSEC source: 0001209191-21-053993 · doc4.xml · nonDerivative · entry 1 Sievers Eric · CIK 0001835116 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,766 F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs. F2 · price: The range of prices for the shares of Common Stock is from $39.50 to $40.29. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. Read SEC document |
| June 14, 2021 Filed Jun 17, 2021 01:23 UTC | BioAtla, Inc. BCAB · Entity 879 | OtherCommon Stock | 23,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-041211 · doc4.xml · nonDerivative · entry 1 Sievers Eric · CIK 0001835116 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,649 F1 · kind: Distribution of the Issuer's shares of Common Stock by Himalaya Parent LLC, of which the reporting person is a member, for no consideration. Read SEC document |
| December 15, 2020 Filed Dec 18, 2020 01:33 UTC | BioAtla, Inc. BCAB · Entity 879 | GrantEmployee Stock Option (right to buy) · Derivative | 77,471 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0000899243-20-034348 · doc4.xml · derivative · entry 1 Sievers Eric · CIK 0001835116 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,471 Underlying: Common Stock · 77,471 shares Expires 2030-12-15 F1 · derivative.exercise_date: The option vests over a period of four years, with 25% of the shares underlying the option vesting on December 15, 2021, the first anniversary of the date of grant, and the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.